KOSDAQBiotech & Pharma200780

Bcworldpharm

₩2,795▲ 0.54%2026-11-18 close
Market Cap
₩29.8B
Turnover
₩30,220,090
Volume
10K
Shares out.
10.7M
PER
—
PBR
0.4×
EPS
-₩231
Dividend Yield
3.57%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩100 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue Flat in the 70 Billion Won Range, Profit Recovery Is the Test

Revenue reached KRW 75.8 billion in 2025, the highest of the 2022–2025 period, but losses attributable to controlling shareholders have continued for two straight years, and the company has named a return to profit in 2027 as its top priority.

  1. 1

    Annual revenue moved within a narrow band from KRW 72.7 billion to KRW 75.8 billion over 2022–2025, showing little growth.

  2. 2

    Net loss attributable to controlling shareholders was KRW 4.43 billion in 2024 and KRW 4.9 billion in 2025, a second consecutive loss with a wider deficit.

  3. 3

    Quarterly operating profit swung widely in 2026, at KRW 1.81 billion in Q1, KRW 147 million in Q2 and KRW 1.21 billion in Q3, with Q3 up sharply from a year earlier.

  4. 4

    The debt-to-equity ratio rose to 143.9% at end-2025 from 136.1% in 2022, and net borrowings were reported at KRW 81.9 billion at end-June 2026.

  5. 5

    The value-up plan disclosed in October 2026 sets a return to profit in 2027 and a medium-to-long-term price-to-book ratio of 1x as targets.

02

Business structure

Bcworldpharm is a research-driven pharmaceutical company founded in 2006 that has expanded its product range on an orally disintegrating tablet (ODT) platform. It launched Subaro-Odi, the first statin-class ODT in Korea, in 2022, and has since broadened the lineup with products such as Telbaro.

In May 2026 it received Ministry of Food and Drug Safety product approval for Ambaro-Odi, a hypertension treatment, and announced its launch in August of the same year. Bonava, a gastric disorder treatment, was also approved in May 2026.

The business is divided into antibiotics, anesthetic and pain medicines, circulatory drugs, and other prescription drugs. Antibiotics accounted for KRW 27.5 billion, or 36.9%, of the KRW 74.8 billion in 2024 revenue, and rose 6.3% year on year to KRW 20.2 billion in Q3 2025.

Its subsidiary operates a carbapenem-dedicated plant designed to block cross-contamination, and a KRW 31 billion antibiotic plant in Wonju, Gangwon Province, has reportedly been built.

Production centers on the Yeoju global manufacturing site and the only antibiotic-dedicated plant in Korea, and the company has expanded CMO partnerships with major domestic pharmaceutical companies.

Exports are concentrated in Southeast Asia, including Vietnam, the Philippines and Thailand, and the company set a target in 2025 of raising the export share to 30% of total revenue within three years.

The company cites its sterile antibiotic manufacturing capability and ODT formulation technology as its competitive strengths.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩19.3B₩100M0.8%
2025Q4₩20.3B₩700M3.5%
2026Q1₩19.8B₩1.8B9.1%
2026Q2₩21B₩100M0.7%
2026Q3₩21.8B₩1.2B5.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩72.7B₩1.9B₩300M2.6%0.4%136.1%
2023₩75.1B₩6.4B₩2.6B8.5%3.2%130.5%
2024₩74.8B₩1.5B-₩4.4B2.0%−5.8%132.0%
2025₩75.8B₩2B-₩4.9B2.6%−6.9%143.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Annual revenue went from KRW 72.7 billion in 2022 to KRW 75.1 billion in 2023 (up 3.3% year on year), KRW 74.8 billion in 2024 (down 0.4%) and KRW 75.8 billion in 2025 (up 1.3%), with 2025 the largest year of the 2022–2025 period.

Operating profit rose from KRW 1.86 billion in 2022 to KRW 6.37 billion in 2023 (up 241.9%), then fell to KRW 1.5 billion in 2024 (down 76.4%) before recovering to KRW 2 billion in 2025 (up 33.1%).

The operating margin was 2.6% in 2022, 8.5% in 2023, 2.0% in 2024 and 2.6% in 2025, so apart from 2023 margins stayed at low levels.

Net income attributable to controlling shareholders was KRW 281 million in 2022 and KRW 2.63 billion in 2023 (up 836.3%), then turned to a net loss of KRW 4.43 billion in 2024 and widened to a net loss of KRW 4.9 billion in 2025.

Net loss including non-controlling interests was KRW 3.14 billion in 2025, a different figure, with the gap coming from non-controlling interests.

The company attributed the profit decline mainly to slower revenue growth and a change in its cost structure, and also cited higher inventory from facility investment and new product introductions, as well as financial cost burdens.

On a quarterly basis, revenue was KRW 19.3 billion in Q3 2025, KRW 20.3 billion in Q4 2025 (up 5.4% quarter on quarter), KRW 19.8 billion in Q1 2026 (down 2.2%), KRW 21 billion in Q2 2026 (up 5.7%) and KRW 21.8 billion in Q3 2026 (up 4.2% quarter on quarter and up 13.4% year on year).

Operating profit was KRW 1.81 billion in Q1 2026, the highest of the last five quarters, fell to KRW 147 million in Q2, and recovered to KRW 1.21 billion in Q3.

Net income attributable to controlling shareholders turned positive at KRW 333 million in Q1 2026, then posted net losses of KRW 1.13 billion in Q2 and KRW 474 million in Q3. The combined net loss attributable to controlling shareholders over the last four quarters is KRW 2.26 billion.

05

Industry analysis

Orally disintegrating tablets can be taken without water, which improves ease of dosing for patients who have difficulty swallowing and for the elderly. The company's investor relations material put the 2022 global market for this dosage form at USD 15.65 billion.

In the domestic prescription environment, the 2024–2025 dispute between doctors and the government reduced patient visits, and the company attributed its soft 2025 performance to this external factor.

In antibiotics, a 2018 Ministry of Food and Drug Safety requirement to separate antibiotic production lines from other lines raised facility investment burdens, and industry observers view the company's dedicated plants as a response to this.

Global demand for carbapenem antibiotics has also been rising, mainly in Southeast Asia, where medical infrastructure is weaker.

In September 2026 the company announced it had been selected as the lead research institution for an AI-based candidate discovery project under a government SME technology innovation program, aimed at identifying lead compounds against antibiotic resistance, with a quantum-computing chemistry firm as a joint research partner.

Many listed peers in the sector are large contract manufacturers or biopharmaceutical companies, so the company's closer comparison is with mid-sized pharmaceutical firms focused on prescription drugs.

Revenue has stayed in the 70 billion won range over 2022–2025, and the company's view is that earnings recovery depends more on commercializing new products and improving cost structure than on market growth.

06

Outlook

For 2026 the company set out a growth strategy built on timely new product launches, cost innovation, facility and operations automation, and AI-based R&D. The new products include Bonava, approved in May 2026, and Ambaro-Odi, launched in August 2026.

Its subsidiary is pursuing the launch of a pediatric treatment for severe drooling and aims to establish a foothold for its carbapenem antibiotics in global markets.

Overseas, the company is pursuing contract manufacturing and partnership agreements with global pharmaceutical companies in Japan and has discussed cooperation with a top-five Canadian pharmaceutical company, with plans to expand into the United States and Latin America from there.

The value-up plan approved by the board on 16 October 2026 and disclosed on 19 October sets a medium-to-long-term price-to-book ratio target of 1x and aims for a return to profit so that a price-earnings ratio can be calculated again.

The company plans to pursue a return to profit in 2027 through higher revenue, cost improvement and more efficient inventory management.

However, according to a Medicopharma report, the plan does not include specific targets for reducing borrowings, cutting financial costs, or the sales contribution of individual new products.

The company has said it will maintain stable dividends within distributable profit and expand quarterly preliminary earnings disclosures and investor relations. It also plans to use an AI-based antibiotic-resistance drug discovery project to identify lead compounds that could move into preclinical development.

The next checkpoints are how much new product sales show up in quarterly results and how far the 2027 return-to-profit target has progressed.

07

Valuation

PER
—
PBR
0.4×
ROE
-3.2%
EPS
-₩231
BPS
₩6,771
Dividend per share
₩100

The price-earnings ratio cannot be calculated because net losses attributable to controlling shareholders have continued over the last four quarters, so earnings-based multiple comparisons do not currently apply.

As a result, the reference point shifts to the price-to-book ratio, which is below the 1x medium-to-long-term target the company has set.

The company's value-up plan includes an analysis of the causes of the low price-to-book ratio, and it aims to restore a base for calculating the price-earnings ratio through a return to profit.

The 2025 dividend payout ratio was 25%, and the company has said it qualifies as a high-dividend company under the Restriction of Special Taxation Act. On the financial side, the debt-to-equity ratio was 143.9% at end-2025, higher than 136.1% in 2022.

Reported net borrowings at end-June 2026 exceeded the company's market capitalization. A report said first-half financial costs exceeded operating profit, so the interpretation of valuation hinges on whether operating profit expands alongside easing of financial cost pressure needed for a return to profit.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Expanding new product portfolio

After the May 2026 approval of Bonava, Ambaro-Odi launched in August, broadening the ODT-centered lineup. The company presents these launches as the core means of restoring revenue growth and profitability. Revenue rose for two consecutive quarters from Q2 to Q3 2026.

Overseas expansion target

The company set a target of raising the export share to 30% of total revenue within three years. It is pursuing contract manufacturing and partnerships with global pharmaceutical companies in Japan and discussing cooperation with a top-five Canadian pharmaceutical company. Industry observers note growing Southeast Asian demand for carbapenem antibiotics.

Quarterly profit recovery

Net income attributable to controlling shareholders turned positive at KRW 333 million in Q1 2026. Operating profit in Q3 2026 was KRW 1.21 billion, up 719.6% from a year earlier. The narrowing of losses from Q4 2025 onward could be read as partly reflecting cost improvements.

09

Bear factors

Two consecutive years of net losses

Net loss attributable to controlling shareholders widened from KRW 4.43 billion in 2024 to KRW 4.9 billion in 2025. Operating profit recovered to KRW 2 billion in 2025, but it did not cover the net loss after financial costs.

Borrowing burden and financial costs

The debt-to-equity ratio rose to 143.9% at end-2025, higher than in 2022. According to a Medicopharma report, consolidated borrowings were KRW 85.8 billion and net borrowings KRW 81.9 billion at end-June 2026, and first-half financial costs of KRW 2.4 billion exceeded operating profit of KRW 2 billion. The company did not set a numerical borrowing reduction target in its plan.

Flat revenue and quarterly volatility

Revenue stayed in the 70 billion won range, from KRW 72.7 billion in 2022 to KRW 75.8 billion in 2025. Operating profit in Q2 2026 fell to KRW 147 million, down 91.8% from the previous quarter, and the quarter swung to a net loss attributable to controlling shareholders. Because quarterly profit has been volatile, it is not yet clear whether the recovery will be sustained.

10

Risk factors

Financial structure

The debt-to-equity ratio rose to 143.9% at end-2025, and net borrowings are large. If financial costs exceed operating profit, the return to net profit attributable to controlling shareholders could be delayed. The value-up plan does not give numerical targets for reducing borrowings or cutting financial costs.

Industry and policy

The company attributed the slowdown in 2025 performance partly to fewer patient visits caused by the dispute between doctors and the government. The antibiotic business is subject to regulatory conditions, including Ministry of Food and Drug Safety production facility requirements and changes to product approvals. Changes in the prescribing environment for key products could directly affect revenue.

Execution

The 2027 return-to-profit target and the 30% export share target depend on new product sales and realizing overseas partnerships. The cooperation in Japan and Canada has been reported at the discussion stage. Higher inventory and facility investment burdens could offset gains from cost improvements.

11

What to watch next

  1. January–February 2027 (expected)

    Preliminary Q4 and full-year 2026 results. The checkpoint is whether the quarterly swings in operating profit settle into a clear annual trend and whether the annual operating margin exceeds the 2.6% recorded in 2025.

  2. End of March 2027

    Statutory deadline for the 2026 annual report. Full-year revenue, net income attributable to controlling shareholders and the debt-to-equity ratio are confirmed in the DART annual filing. The 2026 general shareholders meeting was held on 26 March 2026, so a similar timetable is possible.

  3. Mid-May 2027

    Statutory deadline for the Q1 2027 quarterly report. This is the first quarterly checkpoint for the 2027 return-to-profit target, and the question is whether net income attributable to controlling shareholders stays positive.

  4. During 2027 (timing not set)

    Progress review of the value-up plan disclosed in October 2026. The company has said it will review implementation at least once a year, and whether it sets numerical targets for reducing borrowings and financial costs is the point to watch.

12

Overall view

Bcworldpharm's revenue stayed in the 70 billion won range over 2022–2025, with 2025 the largest year at KRW 75.8 billion.

Profit peaked in 2023 with operating profit of KRW 6.37 billion, after which net losses attributable to controlling shareholders continued for two consecutive years, widening to KRW 4.9 billion in 2025. The 2026 quarterly picture is mixed.

Revenue rose for two consecutive quarters from Q2 to Q3, and Q3 operating profit of KRW 1.21 billion was up sharply from a year earlier, but in Q2 operating profit fell to KRW 147 million and the quarter posted a net loss.

Strengths include the expanding new product lineup including Ambaro-Odi, the export share target, and the recovery in quarterly operating profit. Weaknesses include continued annual losses, a 143.9% debt-to-equity ratio at end-2025, the financial cost burden, and flat revenue.

The value-up plan targets a return to profit in 2027 and a medium-to-long-term price-to-book ratio of 1x, but it does not give numerical targets for reducing borrowings or cutting financial costs.

The next checkpoints are whether operating profit in the Q4 and full-year 2026 results moves beyond quarterly swings, and whether the structure in which financial costs offset operating profit eases. This report is provided for information only and does not present an investment rating or target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. dailypharm.com
  2. apsk.co.kr
  3. medicopharma.co.kr
  4. newsthevoice.com
  5. catch.co.kr
  6. pharmnews.com
  7. hitnews.co.kr
  8. m.news.nate.com
  9. file.alphasquare.co.kr
  10. bcwp.co.kr
  11. edaily.co.kr
  12. kormedi.com
  13. medigatenews.com
  14. bcwp.co.kr
  15. m.news.nate.com
  16. newspim.com
  17. m.dailypharm.com
  18. thebionews.net

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis